Study: CBD Oil Shows Promise for Treatment-Resistant Anxiety in UK Trial

A randomised controlled trial conducted by the University of Oxford has found that high-dose CBD (200mg daily) significantly reduces anxiety symptoms in patients with treatment-resistant generalised anxiety disorder (GAD). The findings, published in the British Journal of Psychiatry, add to a growing body of evidence supporting CBD as a therapeutic option for mental health conditions. The 16-week trial followed 120 patients who had failed to respond to at least two prior treatments, including SSRIs and CBT. Patients receiving CBD reported a 42% reduction in GAD-Q-IV scores compared to 18% for placebo - a statistically significant difference that persisted at 3-month follow-up. Importantly, CBD was well tolerated with no serious adverse events. Mild side effects including drowsiness and dry mouth were reported by approximately 15% of participants. Lead researcher Professor James Waring noted: "These results don't suggest CBD is a first-line treatment for anxiety, but for patients who've run out of options, it represents a meaningful new avenue." The trial used a pharmaceutical-grade CBD product available on prescription in the UK.